StreetAlpha.app
Home › Stocks › ATOS

Atossa Therapeutics, Inc. (ATOS)

$1.59
▼ −8.86%
LAST CLOSE · NOV 20

Atossa Therapeutics develops oral medicines for breast cancer and other breast conditions, based in Seattle. It last closed at $1.59 on Nov 20, down 8.86% on the day. The next earnings report for ATOS is expected around Tue, Feb 9, 2027. For the quarter ended Sep 2026, ATOS reported EPS of -$0.56. Over its last 8 reports the stock moved an average of 3.0% the session after earnings.

AI Auto Pilots
Is ATOS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ATOS.

Key Stats

Last 12 months
Results
Net income
−$34.7M
EPS (diluted)
−$3.86
Free cash flow
−$35.3M
Valuation
Market cap
$15.9M
10.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.6M
At Sep 30
Shareholder equity
$21.7M
Shares outstanding
10.0M
At Jul 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$20.6M−$20.6MFY2021FY2022: −$27.0M−$27.0MFY2022FY2023: −$30.1M−$30.1MFY2023FY2024: −$25.5M−$25.5MFY2024FY2025: −$34.8M−$34.8MFY2025

From ATOS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 9
Estimated date · Time not announced
Reported EPS
-$0.56
Quarter ended Sep 2026
Year ago EPS
-$1.01
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.89Dec '24Mar 2025: -$0.78Mar '25Jun 2025: -$0.98Jun '25Sep 2025: -$1.01Sep '25Dec 2025: -$1.28Dec '25Mar 2026: -$1.11Mar '26Jun 2026: -$0.95Jun '26Sep 2026: -$0.56Sep '26Latest -$0.56
Revenue by quarter
Not enough quarters on file yet.
How ATOS moved after its last 8 reports
Average move the session after a report ±3.0%
Nov 10, 2026Time not announced+0.5%
Aug 7, 2026Time not announced−2.5%
Jan 9, 2026Time not announced−1.2%
Nov 12, 2025Time not announced−1.7%
Aug 12, 2025Time not announced+1.2%
May 13, 2025Time not announced+6.3%
Mar 25, 2025Time not announced−3.3%
Nov 12, 2024Time not announced−7.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ATOSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ATOS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ATOS

Technical Analysis

ATOS · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 31% below its 20 day and 42% below its 50 day average. It is 118% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $1.59, and the nearest resistance the Pivot at $1.64.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 11.9%/day
Key levels
$14.8552 week high+834.0%
$3.47200 day average+118.2%
$2.35100 day average+47.8%
$2.31Swing high (Nov 10)+45.3%
$2.2650 day average+42.1%
$2.0820 day average+30.8%
$1.68Pivot R1+5.7%
$1.64Pivot+3.1%
$1.5952 week low+0.0%
$1.59Last close
$1.55Pivot S1−2.5%
Indicators
RSI (14)26.95Oversold below 30Oversold
MACD-0.17Below its signal lineBearish
Stochastic1.3Near the bottom of its rangeOversold
ADX (14)19.6No clear trend
Williams %R-99.3Oversold below −80, overbought above −20Oversold
CCI (20)-169.2Oversold below −100, overbought above 100Oversold
Rate of change−24.8%Change over 10 sessionsBearish
ATR (14)$0.19Typical daily range, 11.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ATOS

What happened before

See how ATOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ATOS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ATOS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ATOSHow many large options trades hit ATOS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ATOS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲15 buying vs 12 selling
  • ▼Held by funds -3.8 pts
  • ▲Funds holding +3
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3532+9.4%
In funds' top 1000–
Held by funds9.7%13.5%−3.8 pts
New / increased9 / 65 / 9+7.1%
Reduced / sold out6 / 68 / 7−20.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ATOS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ATOS Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 21, 2025Steven C QuayPresident & CEOBuy11,239$0.88$10K
Mar 26, 2025H. Lawrence RemmelDirectorBuy10,000$0.70$7K
Every insider buy and sale for ATOS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ATOS insider trades →

From SEC Form 4 filings by ATOS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ATOS is in one of them and how their past ATOS trades turned out.

ATOS in the AI portfolios
Loading…

ATOS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ATOS in an article yet. Here's the latest on the wider market.

ATOS in the news

ATOS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 6
Who traded ATOS · since 2017
Latest 1 filing
$1K – $15KTraded Oct 25, 2017Filed Aug 6, 2018
PersonTypeAmountTradedFiledDelay
Roger MarshallR · KSBuy$1K – $15KOct 25, 2017Aug 6, 2018285 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Atossa Therapeutics

Atossa Therapeutics is a biopharmaceutical company based in Seattle, Washington, that develops medicines for breast cancer and other breast conditions. Its main product in development is an oral drug called (Z)-endoxifen, which is still being tested in clinical studies. The drug is being studied for women with breast cancer, including for treating early breast cancer and for lowering breast density. The company is also exploring whether the drug could help with some rare diseases.

Headquarters
Seattle, WA
Founded
2009